Abstracts tagged "Takayasu.s arteritis"

Abstract Number: 1554 • ACR Convergence 2022
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
Cameron Rankin¹, Peter Grayson², Bates Gribbons³, Kaitlin Quinn⁴, Christopher Redmond⁵ and Wanxia Tsai¹, ¹NIAMS/NIH, Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³McGovern Medical School, Colleyville, TX, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁵National Institutes of Health, Rockville, MD
Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…
Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Jomana mazareeb¹, shiri keret¹, Abid Awisat¹, Itzhak Rosner², Michel Rozenbaum³, Lisa Kaly¹, Gleb Slobodin¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion Medical Center/Technion, Haifa, Israel, ³Bnei Zion Medical Center, Hertzeliya, Israel
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…
Abstract Number: 1574 • ACR Convergence 2022
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…
Abstract Number: 2227 • ACR Convergence 2022
Active Takayasu Arteritis Is Associated with Plasma and Cellular Measures of Endothelial Dysfunction
Marta Peverelli¹, Andrew Porter¹, Kerri Malone², Allan Kiprianos¹, Tom McKinnon¹, Charis Pericleous¹, Robert Maughan¹ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²European BioInformatics Institute, Hinxton, United Kingdom
Background/Purpose: The accurate assessment of disease activity and progression is a major challenge in Takayasu Arteritis (TA). An improved understanding of disease pathogenesis is required…
Abstract Number: 2228 • ACR Convergence 2022
Development of the Takayasu’s Arteritis Integrated Disease Activity Index
Chiara Marvisi¹, Ertugrul Cagri Bolek², Mark Ahlman³, Hugh Alessi⁴, Christopher Redmond⁵, Peter Merkel⁶, Carlo Salvarani⁷, Kaitlin Quinn⁸ and Peter Grayson⁹, ¹Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ²Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham MD, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity indices that accurately assess inflammation in Takayasu's arteritis (TAK) are needed. While clinical assessment is often considered the gold standard, determining if…
Abstract Number: 2229 • ACR Convergence 2022
Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
Guillaume Goudot¹, Anatole Jimenez², Nassim Mohamedi³, jonas Sitruk³, Lina Khider¹, Hélène Mortelette³, Clément Papadacci², Fabien Hyafil⁴, Mickaël Tanter², Emmanuel Messas¹, Mathieu Pernot² and Tristan Mirault¹, ¹Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, INSERM U970 PARCC, Paris, Ile-de-France, France, ²Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, PSL Research University, Paris, France, ³Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, Paris, Ile-de-France, France, ⁴Nuclear medicine department, Georges Pompidou European hospital, APHP, Universite Paris Cite, INSERM U970 PARCC, Paris, Ile-de-France, France
Background/Purpose: Use of sulphur hexafluoride microbubbles (MB) with ultrasound allow to assess arterial wall vascularization through signal enhancement. The use of ultrafast imaging with MB…
Abstract Number: 0179 • ACR Convergence 2022
Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies
Lauren Pachman¹, Gabrielle Morgan², Wilfredo Marin³, Sabah Kadri³, Kai Lee Yap³ and Amer Khojah⁴, ¹Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁴Umm Al-Qura University, Makkah, Saudi Arabia
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease characterized by proximal weakness and skin rash. Although the exact mechanism of JDM is not…
Abstract Number: 0465 • ACR Convergence 2022
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
Diana Prieto-Peña¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, Pilar Bernabeu⁵, Paloma Vela-Casampere⁶, F. Javier Narváez⁷, Vicente Aldasoro⁸, Olga Maíz⁹, Jesús Carlos Fernández-López¹⁰, Mercedes Freire¹⁰, Rafael Melero¹¹, Juan Ignacio Villa¹², Beatriz Gonzalez-Alvarez¹³, Roser Solans-Laqué¹⁴, José Luis Callejas¹⁵, Carlos Fernandez-Diaz¹⁶, Salvador Garcia-Morillo¹⁷, Mauricio Minguez¹⁸, Cristina Fernández-Carballido¹⁹, Esteban Rubio²⁰, Eugenio De Miguel²¹, Julio Sánchez-Martín²², Esther Fernandez²³, Sheila Melchor²⁴, Eva Salgado-Pérez²⁵, Beatriz Bravo²⁶, Susana Romero Yuste²⁷, Eva Galíndez-Agirregoikoa²⁸, francisca Sivera²⁹, Ivan Ferraz Amaro³⁰, Cristina Hidalgo³¹, Carlos Romero Gomez³², Carles Galisteo³³, Patricia Moya Alvarado³⁴, Noelia Alvarez-Rivas³⁵, Javier Mendizabal³⁶, Juan Carlos Nieto González³⁷, Juan Ramón de Dios³⁸, Jose Luis Andreu³⁹, Nagore Fernandez-Llanio⁴⁰, Eztizen Labrador⁴¹, Enrique Raya Álvarez⁴², Arantxa Conesa⁴³, Francisco Ortiz-Sanjuan⁴⁴, Sara Manrique Arija³², Iñigo Rua-Figueroa⁴⁵, A. García-valle⁴⁶, Miguel Ángel González-Gay⁴⁷ and Ricardo Blanco², ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Hospital General de Alicante, Alicante, Spain, ⁶Hospital General Universitario Alicante, Alicante, Spain, ⁷Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario de Navarra, Pamplona, Spain, ⁹Hospital Univesitario de Donostia, Donostia, Spain, ¹⁰Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹²Hospital Sierrallana, Torrelavega, Spain, ¹³Hospital Nuestra Señora de la Candelaria, Tenerife, Spain, ¹⁴Hospital Vall d’Hebron, Barcelona, Spain, ¹⁵Hospital San Cecilio, Granada, Spain, ¹⁶H, Murcia, Spain, ¹⁷Hospital Virgen del Rocío, Sevilla, Spain, ¹⁸San Juan de Alicante, Alicante, Spain, ¹⁹Agencia Valenciana de Salud, Alicante, Spain, ²⁰HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLE, Spain, ²¹Hospital Universitario La Paz, Madrid, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ²⁶Hospital Virgen de las Nieves, Madrid, Spain, ²⁷Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Elda, Alicante, Spain, ³⁰Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Regional Universitario Málaga, Málaga, Spain, ³³Hospital Parc Tauli,, Sabadel, Spain, ³⁴Hospital Parc Tauli, Barcelona, Spain, ³⁵Hospital San Agustin, Aviles, Spain, ³⁶Complejo Hospitalario de Navarra,, Pamplona, Spain, ³⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁸Hospital de Araba, Araba, Spain, ³⁹Hospital Puerta de Hierro, Madrid, Spain, ⁴⁰Hospital Arnau de Vilanova,, València, Spain, ⁴¹Hospital San Pedro, Logroño, Spain, ⁴²Hospital Universitario San Cecilio, Granada, Spain, ⁴³Hospital Universitario de Castellón, València, Spain, ⁴⁴Hospital Universitario de La Fe, València, Spain, ⁴⁵Hospital Doctor Negrín, Gran Canaria, Spain, ⁴⁶Completo Asistencial Palencia, Palencia, Spain, ⁴⁷Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). However, LVV-GCA and TAK…
Abstract Number: 0491 • ACR Convergence 2022
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Despina Michailidou¹, Bhargavi Duvvuri¹, Runa Kuley¹, David Cuthbertson², Peter Grayson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Antoine Sreih⁷, Kenneth J. Warrington¹¹, Tomas Mustelin¹, Paul Monach¹², Peter Merkel¹³ and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²VA Boston Healthcare System, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…
Abstract Number: 1202 • ACR Convergence 2022
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
Palak Shah¹, Ana Arevalo², Rasha Alaameri³, Brinda Basida⁴, Urja Nagadia⁵, Sanket Basida⁵, shobhana Chaudhari⁶ and Monil Majmundar⁷, ¹Metropolitan Hospital Center, New York Medical College, New York, NY, ²University of Chicago, Chicago, IL, ³New York Medical College/ Metropolitan Program, New York, NY, ⁴DMC/Sinai Grace Hospital, Detroit, MI, ⁵University of Missouri, Columbia, MO, ⁶NYC Health and Hospital/Metropolitan Hospital, New York, NY, ⁷University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Vasculitides are characterized by inflammation of vessel walls with reactive damage to mural structures leading to compromise of the lumen. Vasculitides also accelerate atherosclerosis…
Abstract Number: 1550 • ACR Convergence 2022
Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
SEMA KAYMAZ-TAHRA¹, Salih Ozguven², Nuh Filizoglu², Ali Ugur Unal³, Fatma Alibaz-Oner⁴, Tunc Ones², Tanju Yusuf Erdil² and Haner Direskeneli⁵, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ³Marmara University School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Iliofemoral artery disease, which is commonly observed in severe atherosclerosis, may also be present in Takayasu's arteritis (TAK). In this study we aimed to…
Abstract Number: 0503 • ACR Convergence 2021
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Kaitlin Quinn¹, Mark A. Ahlman², Hugh Alessi³, Ashkan Malayeri², Jamie Marko², Elaine Novakovich² and Peter Grayson⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
Abstract Number: 1194 • ACR Convergence 2021
A Module on Large Vessel Vasculitis for Learners in Rheumatology
David Shoemaker¹, Stamatina Danielides¹, Abhishek Nandan¹, Huzaefah Syed², Beth Rubinstein¹ and Seema Patel¹, ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Of the rheumatic disorders that learners are expected to know, the vasculitides are among the hardest to grasp. Their pathogenesis is not well-established, they…
Abstract Number: 1728 • ACR Convergence 2021
Takayasu’s Arteritis and Pregnancy: A Meta-analysis
Aine Gorman¹, Leah Rooney², Matthew Turk¹, Louise Moore³, Jared Bierbrier⁴, Celine O'Brien⁵, Anne Clohessy⁶, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala McAuliffe⁹ and Douglas Veale¹⁰, ¹St Vincents Hospital, Dublin, Ireland, ²St Vincent's University Hospital, Dublin, Ireland, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁴McMaster University, Hamilton, ON, Canada, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶National Maternity Hopistal, Dublin, Ireland, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹National Maternity Hopsital Dublin, Dublin, Ireland, ¹⁰University College Dublin, Dublin, Ireland
Background/Purpose: Takayasu’s arteritis is a systemic autoimmune disease characterised by large vessel vasculitis. It usually affects women of childbearing age, with 90% of patients diagnosed…
Abstract Number: 1862 • ACR Convergence 2021
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Kristina Wells¹, Fernanda Gutierrez-Rodrigues², Bhavisha Patel², Kaitlin Quinn³, Keith Sikora¹, Neal Young⁴ and Peter Grayson⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institues of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].